These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35190777)

  • 1. Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon.
    Atoui A; Bou Zerdan M; El Mahmoud A; Chamseddine N; Hamad L; Assi HI
    Int J Breast Cancer; 2022; 2022():1218128. PubMed ID: 35190777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings.
    Hashmi AA; Bukhari U; Najam J; Dowlah T; Ali AH; Diwan MA; Anjali F; Sham S; Zia S; Irfan M
    Cureus; 2023 Jun; 15(6):e40066. PubMed ID: 37425505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population.
    Wang J; Sang D; Xu B; Yuan P; Ma F; Luo Y; Li Q; Zhang P; Cai R; Fan Y; Chen S; Li Q
    Medicine (Baltimore); 2016 May; 95(18):e3518. PubMed ID: 27149453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy.
    Tan S; Fu X; Xu S; Qiu P; Lv Z; Xu Y; Zhang Q
    Pathol Oncol Res; 2021; 27():1609972. PubMed ID: 34987312
    [No Abstract]   [Full Text] [Related]  

  • 7. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer.
    Zhang X; Wang D; Liu Z; Wang Z; Li Q; Xu H; Zhang B; Liu T; Jin F
    Quant Imaging Med Surg; 2020 Jan; 10(1):197-210. PubMed ID: 31956542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
    Bonnefoi H; Litière S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmström P; Werutsky G; Bogaerts J; Bergh J; Cameron DA;
    Ann Oncol; 2014 Jun; 25(6):1128-36. PubMed ID: 24618153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
    Lv M; Li B; Li Y; Mao X; Yao F; Jin F
    Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
    Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H
    Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
    Luangdilok S; Samarnthai N; Korphaisarn K
    J Breast Cancer; 2014 Dec; 17(4):376-85. PubMed ID: 25548587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
    Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: correlation with molecular phenotype].
    Blanco Sánchez A; Yébenes L; Berjón A; Hardisson D
    Rev Esp Patol; 2021; 54(1):8-16. PubMed ID: 33455698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
    Alba E; Lluch A; Ribelles N; Anton-Torres A; Sanchez-Rovira P; Albanell J; Calvo L; García-Asenjo JA; Palacios J; Chacon JI; Ruiz A; De la Haba-Rodriguez J; Segui-Palmer MA; Cirauqui B; Margeli M; Plazaola A; Barnadas A; Casas M; Caballero R; Carrasco E; Rojo F
    Oncologist; 2016 Feb; 21(2):150-5. PubMed ID: 26786263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer].
    Liu WQ; Ye JM; Xu L; Liu Q; Zhao JX; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2013 Aug; 51(8):706-9. PubMed ID: 24252676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological complete response and associated factors in breast cancer after neoadjuvant chemotherapy: A retrospective study.
    Gündoğdu A; Uluşahin M; Çekiç AB; Kazaz SN; Güner A
    Turk J Surg; 2024 Mar; 40(1):73-81. PubMed ID: 39036007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neoadjuvant chemotherapy responses and survival rates of patients with different molecular subtypes of breast cancer.
    Zhang H; Zhang X; Jin L; Wang Z
    Am J Transl Res; 2022; 14(7):4648-4656. PubMed ID: 35958459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.